MX2017000862A - Formulacion de factor viii. - Google Patents

Formulacion de factor viii.

Info

Publication number
MX2017000862A
MX2017000862A MX2017000862A MX2017000862A MX2017000862A MX 2017000862 A MX2017000862 A MX 2017000862A MX 2017000862 A MX2017000862 A MX 2017000862A MX 2017000862 A MX2017000862 A MX 2017000862A MX 2017000862 A MX2017000862 A MX 2017000862A
Authority
MX
Mexico
Prior art keywords
factor viii
viii formulation
formulation
relates
factor
Prior art date
Application number
MX2017000862A
Other languages
English (en)
Inventor
Metzner Hubert
Liebing Uwe
Bodenbender Christina
Original Assignee
Csl Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Ltd filed Critical Csl Ltd
Publication of MX2017000862A publication Critical patent/MX2017000862A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)

Abstract

La invención se refiere a composiciones de Factor VIII y su uso.
MX2017000862A 2014-08-04 2015-07-24 Formulacion de factor viii. MX2017000862A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14179732 2014-08-04
PCT/EP2015/066999 WO2016020210A1 (en) 2014-08-04 2015-07-24 Csl behring gmbh

Publications (1)

Publication Number Publication Date
MX2017000862A true MX2017000862A (es) 2017-05-01

Family

ID=51298563

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017000862A MX2017000862A (es) 2014-08-04 2015-07-24 Formulacion de factor viii.

Country Status (17)

Country Link
US (1) US10238718B2 (es)
EP (1) EP3177317B1 (es)
JP (1) JP6516829B2 (es)
KR (1) KR102192494B1 (es)
CN (1) CN106687126B (es)
AU (1) AU2015299224B2 (es)
BR (1) BR112017002090B1 (es)
CA (1) CA2956412A1 (es)
DK (1) DK3177317T3 (es)
ES (1) ES2788870T3 (es)
IL (1) IL250343B (es)
MX (1) MX2017000862A (es)
NZ (1) NZ729629A (es)
PL (1) PL3177317T3 (es)
RU (1) RU2689338C2 (es)
SG (2) SG11201700550YA (es)
WO (1) WO2016020210A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
JP7113429B2 (ja) 2016-11-29 2022-08-05 Ｓｐｉｂｅｒ株式会社 タンパク質組成物、その製造方法及び熱安定性向上方法
WO2018132874A1 (en) * 2017-01-19 2018-07-26 Csl Limited Method of preventing an immune response with alpha- 1 anti-trypsin
EP3706720A4 (en) 2017-11-07 2021-08-18 Rani Therapeutics, LLC COAGULATION FACTOR PREPARATIONS TO BE ADMINISTERED INTO INTESTINAL TRACT TISSUE BY MEANS OF A MEDICINAL DELIVERY DEVICE
CN113105562B (zh) * 2018-09-26 2023-12-01 安源医药科技（上海）有限公司 突变型单链人凝血因子viii在制备融合蛋白中的应用
CN112138149A (zh) * 2019-06-28 2020-12-29 北京基科晟斯医药科技有限公司 重组凝血因子viii制剂
US20220380439A1 (en) 2020-11-09 2022-12-01 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
ATE148165T1 (de) 1989-07-24 1997-02-15 Bayer Ag Stabilisierung von hochgereinigten proteinen
DE4001451A1 (de) 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
DE4111393A1 (de) 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
WO1993022336A1 (en) 1992-04-30 1993-11-11 Alpha Therapeutic Corporation Improved solubilization and stabilization of factor viii complex
SK282483B6 (sk) * 1992-10-02 2002-02-05 Genetics Institute, Inc. Stabilná kompozícia koagulačného faktora VIII, spôsob jej prípravy a stabilizácie
GB9501040D0 (en) 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
SE9501189D0 (sv) 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
US6586573B1 (en) * 1999-02-22 2003-07-01 Baxter International Inc. Albumin-free Factor VIII formulations
ES2411007T3 (es) 2001-10-10 2013-07-04 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
MXPA06006886A (es) * 2003-12-19 2006-09-04 Novo Nordisk Healthcare Ag Composiciones estabilizadas de polipeptidos del factor vii.
KR100624013B1 (ko) * 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
US7523304B2 (en) * 2005-11-22 2009-04-21 Ntt Docomo, Inc. Generation of set coverings with free riders, and generation of ordered sets of meeting points, in systems which include, but are not limited to, systems for broadcast encryption and systems for certificate revocation
EP1986612B1 (en) 2006-02-07 2012-09-12 Shire Human Genetic Therapies, Inc. Stabilized composition of glucocerebrosidase
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
US7982010B2 (en) 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
US7985839B2 (en) 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
AU2007245190B2 (en) 2006-03-31 2011-07-21 Takeda Pharmaceutical Company Limited Pegylated factor VIII
WO2008077616A1 (en) 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
JP5702066B2 (ja) 2006-12-27 2015-04-15 ネクター セラピューティクス 解離可能な連結を有するフォンウィルブランド因子および第ｖｉｉｉ因子のポリマー共役体
EP1988101A1 (en) 2007-05-04 2008-11-05 Novo Nordisk A/S Improvement of factor VIII polypeptide titers in cell cultures
AU2008274195B2 (en) 2007-07-11 2013-09-05 Novo Nordisk A/S Purification of factor VIII using a mixed-mode or multimodal resin
US8173597B2 (en) 2007-11-09 2012-05-08 Baxter International Inc. Modified recombinant factor VIII and von Willebrand factor and methods of use
EP2626080A3 (en) 2008-02-27 2014-03-05 Novo Nordisk A/S Conjugated factor VIII molecules
PL2337580T3 (pl) * 2008-09-03 2012-08-31 Octapharma Ag Stabilizowane kompozycje czynnika VIII produkowanego metodami rekombinacji genetycznej
MX2011004085A (es) 2008-10-17 2011-09-27 Baxter International Factores sanguineos modificados que comprenden un bajo grado de polimero soluble en agua.
ES2706296T3 (es) 2008-11-07 2019-03-28 Univ Connecticut Formulaciones de Factor VIII
ES2401965T3 (es) 2009-02-19 2013-04-25 Novo Nordisk A/S Modificación de Factor VIII
WO2010115866A1 (en) 2009-04-06 2010-10-14 Novo Nordisk A/S Targeted delivery of factor viii proteins to platelets
GB0915480D0 (en) 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
CN102812039B (zh) 2010-02-16 2016-01-20 诺沃—诺迪斯克有限公司 缀合蛋白质
EP2536753B1 (en) 2010-02-16 2017-12-20 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
CN102770450B (zh) 2010-02-16 2015-12-02 诺沃—诺迪斯克有限公司 因子viii融合蛋白
US8859731B2 (en) 2010-04-21 2014-10-14 Novo Nordisk A/S Selective modification of proteins
US20130183280A1 (en) 2010-07-15 2013-07-18 Novo Nordisk A/S Stabilized factor viii variants
DK2616090T3 (da) 2010-09-17 2023-09-18 Takeda Pharmaceuticals Co Stabilisering af immunoglobuliner gennem vandig formulering med histidin ved svag syre til neutral ph
CN103917554B (zh) * 2011-10-18 2017-03-08 杰特有限公司 用于改善重构后纯化的因子viii的稳定性的方法
CN102580062B (zh) * 2012-03-09 2017-03-08 中国医学科学院输血研究所 人凝血因子VIII与vWF复合物或人凝血因子VIII制剂的干热处理稳定剂
US20150080309A1 (en) * 2012-04-24 2015-03-19 Nova Nordisk A/S Compounds Suitable for Treatment of Haemophilia
EP2882457A1 (en) * 2012-08-13 2015-06-17 Novo Nordisk A/S Liquid factor viii formulations

Also Published As

Publication number Publication date
NZ729629A (en) 2021-12-24
IL250343A0 (en) 2017-03-30
BR112017002090B1 (pt) 2021-06-01
AU2015299224B2 (en) 2019-06-20
RU2017106159A (ru) 2018-09-06
BR112017002090A2 (pt) 2018-01-30
KR102192494B1 (ko) 2020-12-18
EP3177317A1 (en) 2017-06-14
RU2017106159A3 (es) 2018-11-28
ES2788870T3 (es) 2020-10-23
DK3177317T3 (en) 2020-06-15
PL3177317T3 (pl) 2020-07-27
JP6516829B2 (ja) 2019-05-22
CA2956412A1 (en) 2016-02-11
EP3177317B1 (en) 2020-03-18
KR20170040327A (ko) 2017-04-12
RU2689338C2 (ru) 2019-05-27
IL250343B (en) 2020-10-29
CN106687126B (zh) 2020-07-28
JP2017528440A (ja) 2017-09-28
WO2016020210A8 (en) 2016-04-28
SG11201700550YA (en) 2017-02-27
CN106687126A (zh) 2017-05-17
AU2015299224A1 (en) 2017-03-23
US20170252412A1 (en) 2017-09-07
WO2016020210A1 (en) 2016-02-11
SG10201900598TA (en) 2019-02-27
US10238718B2 (en) 2019-03-26

Similar Documents

Publication Publication Date Title
ZA201701286B (en) Flagellin compositions and uses
EP3166574A4 (en) Cosmetic compositions
ZA201702213B (en) Interleukin-15 compositions and uses thereof
IL247262B (en) Preparations containing cannabinoids and their uses
GB201409348D0 (en) Perfume compositions
IL250568A0 (en) Anti-methanogenic preparations and their uses
ZA201901260B (en) Fragrance compositions
MX2017000862A (es) Formulacion de factor viii.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
GB201502002D0 (en) Uses and compositions
EP3191549A4 (en) Organosiloxane compositions and uses thereof
GB201608762D0 (en) Compositions and uses thereof
SI3220893T1 (sl) Sestavek na osnovi COQ10
IL249695A0 (en) Converted polymyxins and preparations containing them
GB201502026D0 (en) Uses and compositions
GB201501991D0 (en) Uses and compositions
ZA201707872B (en) Compositions comprising anakinra
IL251238A0 (en) Mineral based compounds and their uses
MY167350A (en) Fat-and-oil composition and chocolate
GB201614897D0 (en) Compositions and uses thereof
GB201602409D0 (en) Compositions and uses thereof
GB201522814D0 (en) Compositions and uses thereof
GB201511886D0 (en) Uses and compositions
EP3183330A4 (en) Perfume compositions containing isomeric alkadienals
ZA201807664B (en) Gel compositions